Santiago Manuel Cayetano Lopez

Santiago Manuel Cayetano Lopez

Auto-generated profile, based on publicly available information

Santiago Manuel Cayetano Lopez

Pfizer Inc

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 October 2024 in Journal of Medical Economics
Verified
Journal Article
Open access
AYAlon Yehoshua
Alon Yehoshua
ACAngela D. Cook
Angela D. Cook
MDManuela DiFusco
Manuela DiFusco
ARAbby E. Rudolph
Abby E. Rudolph
ETElizabeth Thoburn
Elizabeth Thoburn
KAKathleen M. Andersen
Kathleen M. Andersen
Conduct a comprehensive analysis of the health and economic outcomes of patients with a COVID-19-associated hospitalization in the US during the predominance of the XBB and JN.1 Omicron lineages. This analysis used data from the PINC AI Healthcare Database (PHD) for all patients with a hospital admission date occurring between February 4, 2023, and February 29, 2024 with an ICD-10-CM code U07.1 "COVID-19" in any position. The data were used to estimate the mean and median length of stay (LOS), mean and median hospitalization cost, and proportion of patients that died in the hospital, by age and level of care (normal ward, intensive care [ICU], invasive mechanical ventilation [IMV]). LOS, hospitalization costs, and inpatient mortality increased with both the level of care and age. Patients not receiving ICU care had the shortest LOS, lowest inpatient mortality, and lowest hospitalization costs. LOS, hospitalization costs, and inpatient mortality were higher for those receiving ICU care and highest for those receiving IMV in the ICU. Within each level of care (normal ward, ICU without IMV, and ICU with IMV), the LOS, inpatient mortality, and hospitalization cost generally increased with age, indicating that older adults with COVID-19 required a longer recovery period, have a higher likelihood of death, and accrue higher costs. However, the proportion of pediatric patients with an ICU admission and/or IMV usage remained high. The PHD data may not be representative of all hospitalized patients in the US. These findings suggest that COVID-19 continues to have severe and costly consequences in all age groups, but particularly for older adults including long LOS, ICU admission, need for IMV, mortality, and high hospital costs.

25 August 2020 in Pediatric Transplantation
Verified
Journal Article
Closed access
PDF file
SLSantiago Manuel Cayetano Lopez
Santiago Manuel Cayetano Lopez
ADAmy Davis
Amy Davis
MZMatthew Zinn
Matthew Zinn
BFBrian Feingold
Brian Feingold
MGMichael Green
Michael Green
MMMarian G. Michaels
Marian G. Michaels

11 September 2023 in Frontiers in Pediatrics
Verified
Journal Article
Open access
LMLeah J. McGrath
Leah J. McGrath
MMMary M. Moran
Mary M. Moran
TATamuno Alfred
Tamuno Alfred
MRMaya Reimbaeva
Maya Reimbaeva
MDManuela DiFusco
Manuela DiFusco
SLSantiago M. C. Lopez
Santiago M. C. Lopez
Introduction: We compared hospitalization outcomes of young children hospitalized with COVID-19 to those hospitalized with influenza in the United States.Methods: Patients aged 0-<5 years hospitalized with an admission diagnosis of acute COVID-19 (April 2021-March 2022) or influenza (April 2019-March 2020) were selected from the PINC AI Healthcare Database Special Release. Hospitalization outcomes included length of stay (LOS), intensive care unit (ICU) admission, oxygen supplementation, and mechanical ventilation (MV). Inverse probability of treatment weighting was used to adjust for confounders in logistic regression analyses.Results: Among children hospitalized with COVID-19 (n = 4,839; median age: 0 years), 21.3% had an ICU admission, 19.6% received oxygen supplementation, 7.9% received MV support, and 0.5% died. Among children hospitalized with influenza (n = 4,349; median age: 1 year), 17.4% were admitted to the ICU, 26.7% received oxygen supplementation, 7.6% received MV support, and 0.3% died. Compared to children hospitalized with influenza, those with COVID-19 were more likely to have an ICU admission (adjusted odds ratio [aOR]: 1.34; 95% confidence interval [CI]: 1.21–1.48). However, children with COVID-19 were less likely to receive oxygen supplementation (aOR: 0.71; 95% CI: 0.64–0.78), have a prolonged LOS (aOR: 0.81; 95% CI: 0.75–0.88), or a prolonged ICU stay (aOR: 0.56; 95% CI: 0.46–0.68). The likelihood of receiving MV was similar (aOR: 0.94; 95% CI: 0.81, 1.1).Conclusions: Hospitalized children with either SARS-CoV-2 or influenza had severe complications including ICU admission and oxygen supplementation. Nearly 10% received MV support. Both SARS-CoV-2 and influenza have the potential to cause severe illness in young children.

23 November 2021 in The Pediatric Infectious Disease Journal
Verified
Journal Article
Closed access
GPGeralyn M. Bs Palmer
Geralyn M. Bs Palmer
TKTravis R. Ba Kooima
Travis R. Ba Kooima
CHChristopher M. Ba Van Hove
Christopher M. Ba Van Hove
LWLandon L. Bs Withrow
Landon L. Bs Withrow
AGAarabhi Bds Gurumoorthy
Aarabhi Bds Gurumoorthy
SLSantiago M.C. Lopez
Santiago M.C. Lopez
Background: American Indian (AI) children are at increased risk for severe disease during lower respiratory tract infection (LRTI). The reasons for this increased severity are poorly understood. The objective of this study was to define the clinical presentations of LRTI and highlight the differences between AI and non-AI previously healthy patients under the age of 24 months. Methods: We performed a retrospective chart review between October 2010 and December 2019. We reviewed 1245 patient charts and 691 children met inclusion criteria for this study. Data records included demographics, clinical, laboratory data, and illness outcomes. Results: Of 691 patients, 120 were AI and 571 were non-AI. There was a significant difference in breast-feeding history (10% of AI vs. 28% of non-AI, P < 0.0001) and in secondhand smoke exposure (37% of AI vs. 21% of non-AI, P < 0.0001). AI children had increased length of hospitalization compared with non-AI children (median of 3 vs. 2 days, P < 0.001). In addition, AI children had higher rates of pediatric intensive unit admission (30%, n = 37) compared with non-AI children (11%; n = 67, P < 0.01). AI children also had higher rates (62.5%, n = 75) and duration of oxygen supplementation (median 3 days) than non-AI children (48%, n = 274, P = 0.004; median 2 days, P = 0.0002). On a multivariate analysis, AI race was an independent predictor of severe disease during LRTI. Conclusions: AI children have increased disease severity during LRTI with longer duration of hospitalization and oxygen supplementation, a higher rate of oxygen requirement and Powered by Editorial Manager and ProduXion Manager from Aries Systems Corporation pediatric intensive care unit admissions, and a greater need for mechanical ventilation. These results emphasize the need for improvement in health policies and access to health care in this vulnerable population.

13 November 2025 in American Journal of Epidemiology
Verified
Journal Article
Open access
KAKathleen M Andersen
Kathleen M Andersen
LMLeah J McGrath
Leah J McGrath
KAKristen E Allen
Kristen E Allen
FKFarid L Khan
Farid L Khan
TYTiange Yu
Tiange Yu
LPLaura Puzniak
Laura Puzniak
Purpose: To describe a novel data ecosystem and quantify improvements in documented COVID-19 vaccine uptake using closed claims data and state vaccine registries. Methods: De-identified data from administrative claims were linked via tokenization to state vaccine registry data from two states with mandatory vaccine reporting. COVID-19 vaccine uptake in claims alone versus supplemented with registry data was measured separately for original wildtype, BA.4/5-adapted bivalent, and XBB.1.5-adapted formulations. Results: There were over 9 million individuals included in each formulation distribution study period. Using claims data alone versus with additional state registry data, 20% versus 57% of individuals had documented receipt of a primary wildtype series (≥2 doses of two-dose or ≥ 1 of single-dose series), 7% versus 10% BA.4/5-adapted bivalent, and 6% versus 8% XBB.1.5-adapted COVID-19 vaccine. Most claims-based vaccination events were captured with drug, rather than procedure, codes. Individuals with Medicaid-based insurance were less likely to be captured as vaccinated in claims data. Conclusions: The addition of state vaccine registries increased COVID-19 vaccine capture by 182% for primary wildtype series, 41% BA.4/5-adapted bivalent, and 38% XBB.1.5-adapted formulations. Tokenization of claims data to vaccine registries presents an opportunity for more accurate estimates of vaccine uptake and effectiveness than claims data alone.

28 September 2023 in Pediatric Research
Verified
Journal Article
Open access
PDF file
KIKhaled A. Ismail
Khaled A. Ismail
MMMalini Mukherjee
Malini Mukherjee
MKMichael S. Kareta
Michael S. Kareta
SLSantiago M. C. Lopez
Santiago M. C. Lopez
Background Lower respiratory tract infection (LRTI) including pneumonia, bronchitis, and bronchiolitis is the sixth leading cause of mortality around the world and leading cause of death in children under 5 years. Systemic immune response to viral infection is well characterized. However, there is little data regarding the immune response at the upper respiratory tract mucosa. The upper respiratory mucosa is the site of viral entry, initial replication and the first barrier against respiratory infections. Lower respiratory tract samples can be challenging to obtain and require more invasive procedures. However, nasal wash (NW) samples from the upper respiratory tract can be obtained with minimal discomfort to the patient. Method In a pilot study, we developed a protocol using NW samples obtained from hospitalized children with LRTI that enables single cell RNA sequencing (scRNA-seq) after the NW sample is methanol-fixed. Results We found no significant changes in scRNA-seq qualitative and quantitative parameters between methanol-fixed and fresh NW samples. Conclusions We present a novel protocol to enable scRNA-seq in NW samples from children admitted with LRTI. With the inherent challenges associated with clinical samples, the protocol described allows for processing flexibility as well as multicenter collaboration. Impact There are no significant differences in scRNA-seq qualitative and quantitative parameters between methanol fixed and fresh Pediatric Nasal wash samples. The study demonstrates the effectiveness of methanol fixation process on preserving respiratory samples for single cell sequencing. This enables Pediatric Nasal wash specimen for single cell RNA sequencing in pediatric patients with respiratory tract infection and allows processing flexibility and multicenter collaboration.